Our take on the REACH losmapimod clinical trial results

https://is1-ssl.mzstatic.com/image/thumb/Podcasts126/v4/fb/22/6e/fb226e19-eefb-a965-c00c-669e7d76ec65/mza_14782204608570097893.jpg/600x600bb.jpg

MyFSHD

Peter L Jones, PhD

106 episodes

1 week ago

MyFSHD is about education and personal empowerment for the worldwide facioscapulohumeral muscular dystrophy (FSHD) community. Here we have discussions and commentary hosted by FSHD researcher Peter Jones, PhD, on many things of interest to the FSHD community. Learn about the science behind the different FSHD therapeutic approaches, FSHD pathology, family genetics and FSHD diagnostics. We will discuss upcoming clinical trials and what to look forward to. You will get to understand how you can be better prepared, become involved, and help contribute to defeating FSHD once and for all.

Non-Profit

Business

RSS

All content for MyFSHD is the property of Peter L Jones, PhD and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Non-Profit

Business

https://d3t3ozftmdmh3i.cloudfront.net/production/podcast_uploaded_nologo/22295197/22295197-1645580596706-aed48aa3a162b.jpg

Our take on the REACH losmapimod clinical trial results

MyFSHD

1 hour 58 minutes 20 seconds

1 year ago

Our take on the REACH losmapimod clinical trial results

"I always tell the truth, even when I lie." Today we are joined by our CRISPR Goddess and cover the Fulcrum Therapeutics REACH phase 3 clinical trial data release and discuss our journey with Fulcrum from the beginning. While very disappointing from several aspects, in the end a lot of benefit truly has been gained for the FSHD field and we are grateful for Fulcrum's contributions to help others going forward. And there are many others coming along, this is the beginning and not the end for FSHD therapeutics.